Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, July 4, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Galena Biopharma, Inc. (NASDAQ: GALE), PTC Therapeutics, Inc. (NASDAQ: PTCT) and Theravance Biopharma, Inc. (NASDAQ: TBPH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4461-100free.
Actavis plc Analyst Notes
On July 1, 2014, Actavis plc (Actavis) announced that it has appointed new members to its Board of Directors including Brenton L. Saunders, CEO and President of Actavis, Nesli Basgoz, M.D. and Christopher J. Coughlin, both of whom are former members of the Board of Forest Laboratories, Inc. The Company also announced that Paul M. Bisaro, former Chairman and CEO of Actavis, has been named to the newly created position of Executive Chairman of the Board. Actavis informed that these changes to the Board follow the completion of its acquisition of Forest Laboratories, Inc., and are effective until the Company's next annual meeting of shareholders in May 2015. According to Actavis, the new Board will have several standing committees which include Audit and Compliance, Compensation, Nominating and Corporate Governance, and Operations and Innovation. Additionally, the Company stated that Sigurdur Olafsson has resigned from the Actavis Board. The full analyst notes on Actavis are available to download free of charge at:
Celldex Therapeutics, Inc. Analyst Notes
On July 1, 2014, Celldex Therapeutics, Inc.'s (Celldex Therapeutics) stock increased by 6.13%, closing at $17.32. Over the past three-day trading period, Company's stock went up by 3.40%, compared to the Nasdaq Composite which gained 1.82% during the same trading period. The full analyst notes on Celldex Therapeutics are available to download free of charge at:
Galena Biopharma, Inc. Analyst Notes
On July 1, 2014, Galena Biopharma, Inc. (Galena Biopharma) announced that the Company has received the notice of allowance of a U.S. Patent for NeuVax™ (nelipepimut-S). According to the Company, the NeuVax patent covers the use of NeuVax alone or in combination with an adjuvant and/or other agents (e.g. other drugs such as Herceptin® (trastuzumab; Genentech/Roche)) in patients with a fluorescence in situ hybridization (FISH) rating of less than about 2.0, to prevent recurrence of any HER2/neu expressing tumor. Additionally, Galena Biopharma stated that the NeuVax patent provides the Company with coverage for any tumor expressing low-to-intermediate levels of HER2. Commenting on the development, Galena Biopharma President and CEO, Mark J. Ahn, Ph.D., said "This allowance further strengthens our broad patent estate for NeuVax, covering all tumor types expressing low-to-intermediate levels of HER2 both as a monotherapy and in combination with other agents." The full analyst notes on Galena Biopharma are available to download free of charge at:
PTC Therapeutics, Inc. Analyst Notes
On June 30, 2014, PTC Therapeutics, Inc. (PTC Therapeutics) announced that it has received the Parent Project Muscular Dystrophy's (PPMD) Path to Progress award at PPMD's Annual Connect Conference in Chicago, Illinois. According to the PTC Therapeutics, the award honors the Company's 16 years of commitment to bring the first-ever therapy for the underlying cause of the disorder to patients with Duchenne muscular dystrophy (DMD). Commenting on the recognition, Company CEO, Stuart W. Peltz, Ph.D., stated, "We are honored to be recognized by an organization that has had a tremendous impact on advancing the research and development of treatments for DMD. PTC is committed to bringing new treatments to patients that are suffering from rare and neglected diseases." The full analyst notes on PTC Therapeutics are available to download free of charge at:
Theravance Biopharma, Inc. Analyst Notes
On July 1, 2014, Theravance Biopharma, Inc.'s (Theravance Biopharma) stock went up by 6.18%, closing at $33.85. For the past six-month trading session, Company's stock significantly increased by 47.42% compared to the Nasdaq Composite which increased by 9.00% during the same trading session. The full analyst notes on Theravance Biopharma are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.